Voiding Dysfunctions and Prevention after Prostate Biopsy. Prospective Observational Study

Year 2021, , 114 - 119, 01.05.2021

Aykut Başer , Mehmet Murat Baykam , Mustafa Serdar Çağlayan , Cemil Aydın , Muhammet Yaytokgil , Musa Ekici

https://doi.org/10.19127/bshealthscience.853534

Cited By: 1

Abstract

The possible side effects of transrectal ultrasonography-guided prostate biopsy (TRUS-Bx), which is one of the most common procedure of urology practice, are common but tend to limit themselves. TRUS-Bx may be associated with Lower Urinary System Symptoms (LUTS). We aimed to investigate the effects of TRUS-Bx on LUTS and the factors that decrease or increase these effects and to provide information about the exposure periods of these factors. This study is a prospective observational study involving patients undergoing prostate biopsy between August 1st, 2019 to 2020. Detailed history was obtained and physical examinations were evaluated from all patients. Patients' age, PSA levels, prostate volumes, Body-Mass-Index measurements and use of alpha blocker were recorded. The effects of recorded information of patients with prostate biopsy on LUTS and uroflowmetry parameters were investigated. A total of 143 patients were included in the study after determining the exclusion criteria. A significant correlation was found only between Qmax changes after TRUS-Bx and the use of alpha blockers. All patients, have decreased Qmax flow rate observed at postprocedure 1th day compared to baseline values. During the controls performed in the 4th week, while the decrease in patients using alpha blockers reached a significantly higher value than its baseline value, it could not return to its baseline value in patients who do not use alpha blockers. Prostate biopsy is expected to cause a temporary LUTS. The effects on this LUTS can be corrected with the use of alpha blockers.

Keywords

Prostate Biopsy, Voiding Dysfunction, LUTS, Alpha Blockers, International prostate symptom score

Project Number

yok

References

• Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. 1992. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol, 148(5): 1549-1557. DOI: 10.1016/s0022-5347(17)36966-5.
• Bozlu M, Ulusoy E, Doruk E, Cayan S, Canpolat B, Schellhammer PF, Akbay E. 2003. Voiding impairment after prostate biopsy: does tamsulosin treatment before biopsy decrease this morbidity? Urology, 62: 1050. DOI: 10.1016/j.urology.2003.07.006.
• Chung SJ, Jung SI, Ryu JW, Hwang EC, Kwon DD, Park K, Kim JW. 2015. The preventive effect of tamsulosin on voiding dysfunction after prostate biopsy: a prospective, open-label, observational study. Int Urol Nephrol, 47: 711-715. DOI: 10.1007/s11255-015-0955-7.
• Glaser AP, Novakovic K, Helfand BT. 2012. The impact of prostate biopsy on urinary symptoms, erectile function, and anxiety. Curr Urol Rep, 13: 447-454. DOI: 10.1007/s11934-012-0277-6.
• Hodge KK, McNeal JE, Terris MK, Stamey TA. 1989. Random systematic versus ultrasound guided transrectal core biopsies of the prostate. J Urol, 142: 71-74. DOI: 10.1016/s0022-5347(17)38664-0.
• Kaplan SA, Lee JY, O'Neill EA, Meehan AG, Kusek JW. 2013. Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male, 16(4): 169-172. DOI: 10.3109/13685538.2013.844786.
• Klein T, Palisaar RJ, Holz A, Brock M, Noldus J, Hinkel A. 2010. The impact of prostate biopsy and periprostatic nerve block on erectile and voiding function: a prospective study. J Urol, 184: 1447-1452DOI: 10.1016/j.juro.2010.06.021.
• Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer ED. 2011. Complications after prostate biopsy: data from SEER-Medicare. J Urol, 186: 1830-1834. DOI: 10.1016/j.juro.2011.06.057.
• Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, Lotan Y. 2013. Systematic review of complications of prostate biopsy. Eur Urol, 64: 876-892. DOI: 10.1016/j.eururo.2013.05.049.
• Mottet N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Fanti S, Gillessen S, Grummet J, Henry AM, Lam TB, Mason MD, van der KwastTH, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T. 2020. EAU Guidelines, Uroweb.org. European Association of Urology Prostate Cancer Guidelines, URL: http://www.uroweb.org/guideline/prostate-cancer/#5;2020 (access date: 30.07.2020) .
• Namekawa T, Fukasawa S, Komaru A, Kobayashi M, Imamura Y, Ohzeki T, Takagi K, Sato Y, Akakura K, Ichikawa T, Ueda T, 2015. Prospective evaluation of the safety of transrectal ultrasound-guided transperineal prostate biopsy based on adverse events. Int J Clin Oncol, 20: 1185-1191. DOI: 10.1007/s10147-015-0831-6.
• O’Leary MP. 2001. Tamsulosin: current clinical experience. Urology, 58(6 Suppl 1): 42-48; DOI: 10.1016/s0090-4295(01)01346-2.
• Schulman CC, Lock TM, Buzelin JM, Boeminghaus F, Stephenson TP, Talja M, European Tamsulosin Study Group, 2001. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol, 166(4): 1358-1363.
• Sefik E, Eker A, Gunlusoy B, Celik S, Bozkurt IH, Basmaci I, Polat S, Degirmenci T, Ceylan Y. 2020. The effect of alpha blocker treatment prior to prostate biopsy on voiding functions, pain scores and health-related quality-of-life outcomes: A prospective randomized trial. Prog Urol, 30(4): 198-204. DOI: 10.1016/j.purol.2019.12.006.
• Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. 1987. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 317: 909-916. DOI: 10.1056/NEJM198710083171501.
• Zisman A, Leibovici D, Kleinmann J, Cooper A , Siegel Y, Lindner A. 2001. The impact of prostate biopsy on patient well-being: a prospective study of voiding impairment. J Urol, 166: 2242-2246.